Suven advances on securing four product patents in Australia, Eurasia, Israel and USA

Suven Life Sciences is currently trading at Rs. 211.55, up by 4.00 points or 1.93% from its previous closing of Rs. 207.55 on the BSE.

The scrip opened at Rs. 208.00 and has touched a high and low of Rs. 214.60 and Rs. 202.90 respectively. So far 49,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 319.45 on 22-May-2015 and a 52 week low of Rs. 144.35 on 19-Feb-2016.

Last one week high and low of the scrip stood at Rs. 214.60 and Rs. 201.90 respectively. The current market cap of the company is Rs. 2,692.66 crore.

The promoters holding in the company stood at 60.00% while Institutions and Non-Institutions held 7.74% and 32.25% respectively.

Suven Life Sciences (Suven) has secured product patents in Australia, Eurasia, Israel and USA to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

With these new patents, Suven has a total of twenty four granted patents from Australia, seventeen granted patents from Eurasia, nine granted patents from Israel and twenty four granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.